Subgroup Analysis of Patients with No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Versus Investigator's Choice of Endocrine Monotherapy for ER+/HER2-advanced/metastatic Breast Cancer (Mbc).